104
Participants
Start Date
July 1, 2024
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2026
B007
B007 high dose and low dose： Subcutaneous injection was administered on days 1 and 15
Placebo
B007 matched Placebo Subcutaneous injection was administered on days 1 and 15
RECRUITING
Peking University First Hospital, Beijing
RECRUITING
The First Bethune Hospital of Jilin University, Changchun
RECRUITING
Xiangya Hospital Central South University, Changsha
RECRUITING
Sichuan Provincial People's Hospital, Chengdu
RECRUITING
Nanfang Hospital, Southern Medical University, Guangzhou
RECRUITING
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
RECRUITING
Shandong Provincial Qianfoshan Hospital, Jinan
RECRUITING
Shandong University Cheeloo College of Medicine, Jinan
RECRUITING
First People's Hospital of Yunnan Province, Kunming
RECRUITING
Jiangxi Provincial People's Hospital, Nanchang
RECRUITING
The Second Affiliated Hospital of Nanchang University, Nanchang
RECRUITING
Shandong University Cheeloo College of Medicine, Qingdao
RECRUITING
Huashan Hospital, Fudan University, Shanghai
RECRUITING
Shenzhen Hospital of University of Hong Kong, Shenzhen
RECRUITING
Renmin Hospital of Wuhan University, Wuhan
RECRUITING
Tongji Medical College of HUST, Wuhan
RECRUITING
Tangdu Hospital, Xi'an
RECRUITING
Affiliated Hospital of Zunyi Medical College, Zunyi
Shanghai Pharmaceuticals Holding Co., Ltd
INDUSTRY
Shanghai Jiaolian Drug Research and Development Co., Ltd
INDUSTRY